EFFECT OF MYO INOSITOL ON INSULIN RESISTANCE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME EFECTO DEL MYO INOSITOL EN LA RESISTENCIA A LA INSULINA EN MUJERES CON SINDROME DE OVARIO POLIQUISTICO

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder that affects women of reproductive age and is strongly associated with insulin resistance (IR) and hormonal imbalances. IR plays a critical role in the patohopysiology of PCOS, contributing to reproductive dysfunction, menstrual irregularities, and long-term cardiometabolic complications. Convemtional treatment such as metformin are effective but often poorly tolerated. In this context, myo-inositol has emerged as promising alternative due to its role in insulin signaling and its favorable safety profile.

Objetive:To summarize the evidence on the effectiveness of myo-inositol in improving insulin resistance in women with PCOS and its application in clinical nutrition.

Methodology:A descriptive literature review was conducted using PubMed, focusing on studies published between 2010 and 2025, with additional key references included. Keywords such as "myo-inositol", "PCOS", and "insulin resistance" were used. Inclusion criteria targeted human and animal studies evaluating metabolic outcomes and dosage information.

Results:The reviewed evidence supports the use of myo-inositol as an effective agent for improving insulin sensitivity in women with PCOS. Myo-inositol activates AMPK, enhances GLUT-4 translocation, and regulates hormonal balance, leading to improvements in HOMA-IR, fasting insulin, BMI, and menstrual regularity.

Comparative studies with metformin show that while both improve insulin resistance, myo-inositol presents fewer adverse effects, notably gastrointestinal discomfort. Furthermore, clinical trials demonstrate that the optimal dosage is 4 grams daily (divided into two doses of 2 g), showing consistent effectiveness across various PCOS phenotypes.

Discussion: The evidence confirms that myo-inositol improves insulin sensitivity and metabolic parameters in women with PCOS, with a favorable safety profile. As part of a personalized nutrition strategy, it enhances adherence and clinical outcomes, offering a non-pharmacological alternative in PCOS management.